Prolaris plus AI test combines clinical insights and digital pathology, Myriad Genetics states

Prolaris plus AI test combines clinical insights and digital pathology, Myriad Genetics states
Myriad Genetics launches Prolaris AI test

Myriad Genetics has announced the upcoming launch of its Prolaris plus AI Test, scheduled for release at the end of this month.

The new product will be the first and only prostate cancer biomarker test to integrate clinical-pathological factors, an independent molecular score, and independent AI-powered digital pathology. By uniting these elements, Myriad Genetics aims to set a new standard for comprehensive prostate cancer diagnostics. Details regarding availability and implementation are expected to be shared as the launch approaches.

Myriad Genetics recently partnered with Jackie Tohn in a campaign to expand awareness of its hereditary cancer testing and early detection efforts, according to a previous announcement. The company has also outlined plans for advances in precision oncology, with a focus on ultra-sensitive minimal residual disease (MRD) testing highlighted at a Tokyo oncology summit. These initiatives reflect Myriad’s ongoing push into cancer diagnostics technology.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.